Nine months since opening the doors of its Kendall Square workspace for biotechs, Mass Innovation Labs has grown to house seven small and mid-size companies, including one that moved in last month.

Startup C4 Therapeutics, which is commercializing research from Dana-Farber Cancer Institute, arrived in January. In November, San Francisco’s Gritstone Oncology decided to base its Cambridge operation at the Kendall Square space. The duo joined Imagen Biopharma, TCR2 Therapeutics, and Cellaria Biosciences, among others.

Mass Innovation Labs cofounder and chief executive officer Amrit Chaudhuri said his vision in launching the space was to make room for mid-sized biotech companies going through a growth-spurt or young startups that don’t want to commit to an expensive, lengthy lease for lab space.

Mass Innovation Labs is one of two companies that lease fully serviced lab and office space in the Kendall Square area. The other is LabCentral, based near Tech Square. At Mass Innovation, member companies have access to animal testing facilities hosted by the workspace’s partner, Charles River Labs, in that company’s Kendall Square facility down the street.

The workspace is 85 percent full, and Chaudhuri said he intends to lease a second location in Cambridge this year.

CRISPR Therapeutics, one of a cluster of Cambridge biotechs working on gene editing technologies, was the first tenant at the space when it opened in 2015. CRISPR moved out after it received a $335 million investment from German pharmaceutical giant Bayer AG in December.

Nidhi Subbaraman can be reached at nidhi.subbaraman@globe.com.